600671 Hangzhou Tianmushan Pharmaceutical Enterprise
- 7.85
- +0.20+2.61%
Hangzhou Tianmushan Pharmaceutical Enterprise News
Announcement on the Correction of Accounting Errors in the First Quarter Report of Hangzhou Tianmushan Pharmaceutical Co., Ltd. for 2024.
Hangzhou Tianmushan Pharmaceutical Co., Ltd.'s first quarter report for 2024 (corrected)
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2023 Annual Report
Hangzhou Tianmushan Pharmaceutical Co., Ltd. Report for the first quarter of 2024
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2023 Annual Report Summary
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. 2023 Annual Results Forecast Loss
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2023 Third Quarter Report
Semi-annual Report of Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2023
Summary of the 2023 semi-annual report of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the 2023 semi-annual results forecast
Hangzhou Tianmushan Pharmaceutical Co., Ltd. report for the first quarter of 2023
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2022 Annual Report
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2022 Annual Report Summary
ZTE Cai Guanghua Certified Public Accountants (Special General Partnership) Special Instructions on Correcting the Performance Forecast of Hangzhou Tianmusan Pharmaceutical Co., Ltd.
Hangzhou Tianmushan Pharmaceutical Co., Ltd.\'s announcement on the correction of the 2022 annual performance forecast
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2022 Annual Performance Forecast Loss Announcement.docx
ST eye medicine: Hangzhou Tianmushan Pharmaceutical Co., Ltd. Report on the third quarter of 2022
Third quarter report of Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2022
ST eye medicine: Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2022 half-year report
ST eye medicine: summary of the 2022 half-year report of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Analysis
Price Target
No Data
